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ABSTRACT
Ovarian cancer is a leading cause of gynecological malignancy. Cytoreductive surgery
and frontline platinum/taxane-based chemotherapy provides good initial efficacy in the
treatment, but poor long-term patient survival. This is mainly caused by tumor relapse due to
intraperitoneal spreading and ineffective alternate therapies to treat these resistant tumors. The
challenge in the field is to develop strategies that would prove effective in these patients and
extend overall survival.
Over the years, various treatments have been developed for the treatment of cancer
amongst which, adoptive cell immunotherapy has shown promising results. But despite the
efficacy seen in the clinic, there are concerns with the complexity of treatment and associated
side effects. Therefore, there is still a need for better understanding of how different components
of the immune system react to the presence of tumor. In this study, healthy human peripheral
blood mononuclear cells (PBMCs) were used to examine the immune response in a mouse model
with residual human ovarian tumor, where natural killer (NK) cells were found to be the effector
cells that elicited an anti-tumor response. Presence of tumor was found to stimulate NK cell
expansion and cytotoxicity in mice treated intraperitoneally (IP) with PBMCs+Interleukin-2 (IL2). Intravenous (IV) adoptive transfer of isolated NK cells has been attempted in ovarian cancer
patients before, but showed lack of persistence in patients resulting in lack of anti-tumor
efficacy. Experiments in this study highlight the significance of NK cell-cytotoxic response to
tumor, which may be attributed to interacting immune cell types in the PBMC population (when
treated IP), as opposed to clinically used isolated NK cells showing lack of anti-tumor efficacy in
ovarian cancer patients (when treated IV).
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NK cell immunotherapy is mainly limited by insufficient numbers generated for adoptive
transfer, limited in vivo life span after adoptive transfer, lack of cytotoxicity and some logistical
concerns that impede its widespread implementation. Therefore there is a need to develop
methods of NK cell expansion that provide stimulation similar to other immune cell types in the
PBMC population. The second part of this study utilizes a method of in vivo NK cell expansion
using a particle-based approach in which plasma membranes of K562-MB21-41BBL cells (K562
cells expressing membrane-bound IL-21 and 41BB ligand) are used for specific NK cell
expansion from PBMCs. NK cells expanded with this method were cytotoxic, showed in vivo
persistence and biodistribution in different organs.
Collectively, these studies show that NK cells are a major innate immune component that
can recognize and kill the tumor. Their cytotoxic ability, using particle-based stimulation, can be
enhanced for a second-line treatment of relapsed tumors such as in ovarian cancer as well as
other cancer types.
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CHAPTER 1: BACKGROUND
Ovarian cancer: The disease
Ovarian cancer is the most lethal amongst gyenecological malignancies. Due to an
asymptomatic early phase and lack of reliable early detection methods, patients are diagnosed at
an advanced stage of the disease. About 21,000 women are diagnosed each year and 14,000 die
from the disease. This poor prognosis is attributed to metastasis, leading to 5-year survival rates
of 70% and 30% for local and distant metastases respectively (American Cancer Society. Cancer
Facts and Figures. New York: American Cancer Society; 2015).
Ovarian tumors can arise from different locations in the ovary like epithelial cells,
stromal cells or germ cells, but majority (>90%) of the tumors are of epithelial origin. Based on
different histotypes, cancers of epithelial origin are further characterized as high-grade serous
(HGS), low-grade serous (LGS), mucinous, endometroid and clear cell. Amongst these, HGS is
the most prevalent form and the most deadly because of late stage diagnosis when the tumor has
already metastasized. Ovarian cancer is unique in the way it metastasizes, compared to other
solid tumors. Tumor cells shed from the primary tumor site and spread through the peritoneal
cavity, as opposed to following the classical mechanism of intravasation and extravasation to and
from the blood or lymphatic system [1]. After they undergo an epithelial to mesenchymal
transition (EMT), cells from the bulk of the tumor are distributed in the peritoneal cavity, mainly
in the form of spheroids through the ascites fluid that builds up in the cavity as the disease
advances [2]. This is why, despite the advances in the techniques for surgical debulking of the
visible primary tumor, most patients succumb to disease relapse caused by free-floating single
cells or spheroids that cannot be adequately removed by surgery.
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Ovarian Cancer: Therapies
Chemotherapeutics
One of the first agents used intravenously (IV) for the treatment of ovarian cancer,
Cisplatin, was discovered in the 1970s. Single agent response rate with Cisplatin was in the
range of 13-30% [3].

Then, in the early 1990s, second-generation platinum based agent

Carboplatin was introduced. Use of these agents predominantly in combination with
Cyclophosphamide or Anthracyclin showed patient survival rates similar to that with Cisplatin
[4]. These drugs were used as a standard of care for a few years before taxanes were introduced
in the late 1990s. Since then, Carboplatin and Paclitaxel have been used in combination (3-week
cycle) as a standard chemotherapeutic treatment for ovarian cancer [5].
Attempts were made to further improve the efficacy of the platinum/taxane-based
approaches by utilizing more than two agents, together or sequentially but these strategies failed
to show any further improved outcome in the overall patient survival [6]. Despite the successful
outcomes of IV administered platinum/taxane-based therapies, tumor relapse rates remain high
and 5-year survival rates are poor, depending on the site and extent of metastases.
A clinical trial was designed to compare the effects of IV and intraperitoneal (IP)
administration of Cisplatin in previously untreated stage III epithelial ovarian cancer patients.
This study showed a significant improvement in the overall survival of patients receiving
Cisplatin IP (49 months) as compared to patients receiving IV treatment only (41 months) [7].
Several other studies since then, with better combinatorial regimes that were carried out after this
trial also showed better patient survival in favor of IP therapy [8]. Despite the extension in
overall ovarian cancer patient survival offered by IP chemotherapy, there were various
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complications associated with it, such as increased hematologic and gastrointestinal cytotoxicity
amongst other side effects [9].
Recently, a modified form of IP therapy has emerged for the treatment of ovarian cancer
patients, called as hyperthermic IP chemotherapy (HIPEC), which offers some advantages [10].
HIPEC is applied at the time of cytoreductive surgery, without any interval between surgery and
chemotherapy. Also, high volumes of chemotherapy can be delivered while the patient is under
general anesthesia that ensures a homogenous distribution of the drug, which is otherwise
difficult because of abdominal distention and pain. Most importantly, hyperthermia offers
pharmacokinetic benefits and has been shown to improve tumor penetration of Cisplatin and
DNA crosslinking [11, 12].
Even after obtaining data over several years, the utility of HIPEC is not accepted
universally. Techniques, drugs and dosages differ and toxicity related issues with chemotherapy
still remain unaddressed even after implementation of this technique. Even though the treatment
of primary tumors has been improved with advances in chemotherapy regimens, tumor relapse
rates in ovarian cancer patients remain high (70% for advanced stage and 20%-25% for stage I
and II) [13] and there’s a lack of credible second-line options for treating chemotherapy resistant
relapsed tumors. Therefore, the challenge is to develop novel strategies that can be effective in
these patients to prevent/treat relapse, extend progression free and overall survival, improving
quality of life.
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Immunotherapy
Overview
One of the strategies that has gained momentum in the past few years for cancer
treatment is immunotherapy [14]. Under the umbrella of immunotherapy, there are various types
of therapies that hold promise and are under development such as checkpoint inhibition,
antibody-based therapies, cytokine-induced killer (CIK) cell-based therapies, adoptive cell
therapies (ACT) etc.
Checkpoint inhibition: A main challenge that faces immunotherapy in ovarian cancer is
the highly immunosuppressive tumor microenvironment. One of the most promising approaches
towards overcoming this suppression has been the use of immune checkpoint inhibitors. The
rationale behind checkpoint blockade strategy is to block immunomodulatory signals that
dampen T cell responses. Main target molecules are CTLA-4 and PD-1 and PD-Ligand1 (PDL1). Some of the ongoing clinical trials in patients with tumor types such as melanoma, renal cell
carcinoma,

pancreatic

cancer

etc.

are

showing

promising

results

(NCT01666353,

NCT01295827). For ovarian cancer treatment, there are several clinical trials using anti-CTLA-4
(Ipilimumab, Tremelimumab), anti-PD-1 (Nivolumab, Pembrolizumab) and anti-PD-L1 (BMS936559, MEDI4736) antibodies that are underway whose results are awaited in terms of
increasing overall survival of patients [15].
Antibody-based therapies: Some other antibody-based therapies have become well
established in the past fifteen years for several tumor types and many such antibodies are being
used in ovarian cancer treatment as well. For example, Bevacizumab, which is a monoclonal
antibody (mAb) for vascular endothelial growth factor (VEGF), is one of the promising
candidates for ovarian cancer as VEGF gene expression in ovarian tumor tissues correlates with
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poor prognosis [16]. Use of this antibody in combination with chemotherapy showed an increase
in the overall response rate from 11% to 27% [17]. Other antibodies that have shown promising
results in the treatment of ovarian cancer are Cetuximab, Panitumumab, Catumaxomab and some
antibodies targeting tumor-associated macrophages [18].
CIK cell-based therapies: CIK cells are a heterogeneous population of immune cells
stimulated by multiple cytokines and are known to show anti-tumor activity [19] and CD3+
CD56+ NKT cells have been shown to be main effectors within this population [20]. This
strategy is promising with respect to ovarian cancer because second–line treatment with CIK
cells in advanced epithelial ovarian cancer patients has showed an improved progression-free
survival (with some side-effects) [21]. However, its effect on overall survival of ovarian cancer
patients is still unclear.
Adoptive Cell Therapy: This is a technique that uses anti-tumor lymphocytes for adoptive
transfer into patients, in an autologous or allogeneic setting to induce tumor cytotoxicity. A
seminal study published in 2003 showed clinical evidence that the presence of tumor infiltrating
lymphocytes (TILs) in ovarian cancer patients was associated with favorable prognosis [22]. The
5-year overall survival rate of patients with tumors lacking TILs and the ones that contained
TILs was 4.5% and 38% respectively.

This study suggested that ovarian tumors may be

susceptible to attack by immune cells and provided rationale for therapeutic applications for
ovarian cancer that aim at bolstering immune cell function. Initial clinical trials utilizing ACT for
the treatment of ovarian cancer used ex vivo activated autologous T cells from peripheral blood
that were retargeted to the folate receptor by a bispecific monoclonal antibody [23]. Results
showed an encouraging overall response rate of 27% without any major side effects. This study
established that autologous T cells, if specifically redirected, could result into tumor regression
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with minimal off-target effects. Alternatively, another study utilized endogenous TILs for T cell
transfer instead of peripheral T cells. Patients were treated with TILs following surgical
debulking of the tumors and chemotherapy. There was a 100% 3-year progression-free survival
rate observed in these patients as compared to 67.5% in the group that received chemotherapy
only [24]. Despite the promising anti-tumor effects observed in patients with different tumor
types with ACT of autologous or allogeneic lymphocytes, many types of adverse effects have
been reported. Some of them include cytokine release syndrome, hypothyroidism, vitiligo,
autoimmune thyroiditis etc. [25]. ACT in patients with lymphomas have also been shown to
suffer from respiratory obstruction, perhaps due to T cell induced inflammatory responses [26].
Apart from these side effects, graft vs host disease (GVHD) has also been one of the major side
effects of ACT that can limit its beneficial effects [27].
T cell based adoptive cell therapy
Development of chimeric antigen receptor (CAR) T cell technology has given a strong
boost to T cell based adoptive cell therapy in several types of cancers, including ovarian cancer.
Studies with the ID8 model of ovarian cancer indicate development of anti-tumor immunity in
mice and tumor free survival with no relapse. This study utilizes engineered T cells that express
an NKG2D CAR that imparts specificity to them. After regression of the tumors, mice were also
shown to develop T cell memory, as a result of which 90% of the mice rejected tumor rechallenge [28]. Following promising results in mouse models, some other ovarian tumor specific
antigens are now being utilized for generation of CAR-T cells and their efficacy is being tested
in patients. For example, a phase I clinical trial is using autologous adoptive transfer of CAR-Ts
with specificity towards the folate receptor found on ovarian tumor cells [29] [30]. Such studies
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confirm that large amounts of modified T cells can be safely administered into patients, but there
are some major concerns with off-target effects and cytokine release syndromes, GVHD etc.
[31]. Even though T cell infusions are well tolerated in patients, it failed to show anti-tumor
responses in ovarian cancer patients because of poor trafficking and complications with in vivo
persistence and function [30].
NK cell based adoptive cell therapy
In contrast to T cells, NK cells are lymphocytes of the innate immune system that target
virally infected or transformed tumor cells. The genes coding for receptors on NK cells do not
undergo any rearrangements to give them specificity against particular target antigens, but are
germline encoded and their specificities to certain antigens is pre-determined. The unique feature
of NK cells is that they have diverse inhibitory and activating receptors. Engagement of these
receptors with their corresponding ligands on target cells determines activity of NK cells.
Absence of an inhibitory ligand on the target cell can trigger the NK cell to eliminate the target.
For example, in the case of tumor cells that lack HLA-I on their surface, which is a ligand for
killer immunoglobulin receptor (KIR) on NK cells, NK cells get activated and degranulate to
release granzymes stored in their cytoplasmic granules and kill the target cell. This is also called
as the ‘missing self hypothesis’ of NK cell activation [32]. Because of this unique ability of NK
cells to recognize tumor targets that downregulate class-I MHC molecules, perhaps to evade T
cell mediated killing, they are a very important avenue for developing tumor-targeting strategies.
Autologous NK cell adoptive therapy: NK cells have been exploited for cancer treatment
for a long time using various techniques to activate their cytotoxic ability. One of the strategies
was with cytokines such as IL-2, IL-15, IL-21, IL-18, IL-12 and type-I IFNs administered in vivo
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(systemically)[33]. But systemic administration of cytokines was associated with severe side
effects in patients such as vascular leak syndrome, in addition to Treg cell expansion that directly
inhibits NK cell function [34, 35]. Instead of systemic administration of cytokines, adoptive
transfer of NK cells expanded ex vivo was attempted and showed improved responses in breast
cancer patients [36] without severe side effects. However, this strategy also showed marginal in
vivo anti-tumor responses because autologous NK cells inherently, can be insufficiently
cytotoxic towards tumors [37].
Allogeneic NK cell adoptive therapy: Unlike autologous NK cell transfer, allogeneic
transfer offers benefits because of mismatch between KIRs on donor NKs and KIR ligands in the
host. There was greater anti-tumor activity demonstrated by allogeneic NK cells adoptively
transferred into patients as compared to their own stimulated NK cells. Donors for these cells are
selected based on established KIR mismatch criteria [38]. This strategy has been successful in
solid tumors and leukemia with relatively minimal side effects [39-41]. A very important factor
for the success of this regimen was lymphodepleting the patients before NK cell infusion, either
by total body irradiation (TBI) or by using chemotherapy. Efficacy of this procedure was defined
in a trial with metastatic melanoma and renal carcinoma patients treated with high-dose
cyclophosphamide and fludarabine (Hi-Cy/Flu) chemotherapeutics (lymphodepleting) before
adoptive transfer of NK cells [39]. Efficacy of allogeneic NK cell transfer has also been tested in
solid tumors such as breast and ovarian cancer [42]. In this study, patients did not show optimal
NK cell expansion in vivo following chemotherapy, so they were subjected to TBI in order to
improve expansion. Unfortunately, there was no benefit seen in terms of NK cell expansion.
Also, patient Treg population was found to be increased at 14 days after NK cell infusion, which
may have further limited NK cell expansion. Another drawback with this strategy is that due to
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KIR mismatch in the allogeneic NK cells, they eventually get rejected by the host’s effector T
cells, suppressed by myeloid suppressor cells and are negatively effected by a myriad of other
host factors [43]. Therefore, even after incremental advances in the field of adoptive transfer of
NK cells, we still need to address the problems of optimal in vivo persistence, expansion and
cytotoxicity.
NK cell expansion for clinical applications
For obtaining sufficient numbers of functional NK cells, several methods have been
developed in recent years [44]. NK cells can be expanded from bone marrow, cord blood,
embryonic stem cells and peripheral blood. Irradiated autologous feeder cells, Epstein-Barr
virus-transformed lymphoblastoid cell lines and modified K562 cells have been used for NK cell
expansion in the past [45]. Campana et al showed that large-scale expansion and activation of
NK cells was possible using modified K562 cells that express membrane-bound IL-15 and 41BB ligand (K562-mb15-41BBL) [46]. NK cells expanded with this method, expand several
hundred fold for up to two weeks but then experience senescence [47]. Moreover, this
methodology using feeder cell cultures for NK cell expansion is not completely safe. Firstly,
with co-cultures of NK cells with feeder cells, there is always a possibility of feeder cells or their
genetic material being injected into patients. Secondly, co-culture systems are complex, variable
and require cGMP facilities that make the process less feasible for widespread application.
Thirdly, these is a need for a final check process to ensure that there are no feeder cells present in
the product being infused into patients. In order to overcome these impediments, a novel NK cell
expansion method was developed that did not require live feeder cells but instead used the
plasma membranes obtained from K562-MB15-41BBL cells. Since the membranes of these cells
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express NK stimulating molecules, using just the plasma membranes would be capable of
stimulating NK cells without the drawbacks associated with live feeder cells [48]. Apart from
membrane bound IL-15, K562-MB21-41BBL cells have also been used for expansion of NK
cells showing sustained ex vivo proliferation [49]. Here in this study, we used plasma membranes
derived from K562-MB21-41BBL cells (PM21) and tested the in vivo expansion of NK cells
activated with PM21 particles.
Functional properties of NK cells make them applicable for clinical use in the treatment
of cancers, but there has been limited success in harnessing the complete potential of this cell
type, specially in fighting solid tumor types. In order to develop NK cell therapy to its full
potential, there is a need to fully understand NK cell biology and how it reacts to the presence of
tumor and also device methods for achieving optimal in vivo NK cell expansion, persistence and
tumor cytotoxicity.
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CHAPTER 2: ANTI-OVARIAN TUMOR RESPONSE OF DONOR
PERIPHERAL BLOOD MONONUCLEAR CELLS IS DUE TO
INFILTRATING CYTOTOXIC NK CELLS
Introduction
Ovarian cancer is the second leading gynecological cancer [50]. Although current
chemotherapy using carboplatin-paclitaxel is effective as a first-line therapy, 70% of patients
with advanced disease succumb to tumor relapse within less than five years, despite initial
response to chemotherapy [51]. Thus, there is an urgency to develop strategies for prevention of
tumor relapse and for increasing overall patient survival. The immune system is protective
against

ovarian

cancer

and

thus,

adjuvant

immunotherapy post-surgery

and

with

chemotherapeutics could be effective for preventing relapse and extending survival [22, 52].
Studies show the link between cancer stem cells and ovarian tumor recurrence, and that
treatment with chemotherapeutics selects resistant tumor populations causing increased risk of
tumor relapse [53, 54]. Such resistant tumor cell populations are susceptible to lymphocytemediated lysis, particularly by NK cells [55]. Therefore, NK cell-based adjuvant immunotherapy
could have significant impact on sustaining remission and improving overall treatment efficacy.
Immunotherapy has impacted treatment of multiple cancers. Monoclonal antibody-based
approaches are beneficial for long-term effects, but a challenge is potential escape by tumors
[56]. Adoptive cell therapy (ACT) with different immune cell types, T cells, dendritic cells
(DCs) or NK cells in clinical trials hold promise. A landmark publication in 2003 showed that
the infiltration of T cells into ovarian tumors improved survival [22]. Since tumor infiltrating
immune cells influence the severity and overall disease outcome, attempts have been made to
adoptively transfer TILs after lymphodepletion with successful results in metastatic melanoma
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patients [57, 58]. DCs can activate the adaptive immune system for a robust response against
infection or against transformed cells, and trials using DCs are ongoing (Clinicaltrials.gov
identifier: NCT01875653). DCs function as antigen presenting cells for naïve CD4 and CD8 T
cells [59]. To circumvent the need for T cell “education”, chimeric antigen receptor (CAR)-T
methods can genetically modify patient T cells to express a targeting receptor for a tumor
specific antigen. In contrast to naïve CD4+ and CD8+ T cells that need to be “educated” or
engineered ex vivo, innate NK cells are naturally cytotoxic towards malignant cells [60]. In vitro
studies show that resting NK cells from healthy donors target isolated tumor cells from the
peritoneal ascites of ovarian carcinoma patients [61]. In this respect, ACT using cytolytic NK
cells for cancer treatment is more advantageous since NK cells do not require prior sensitization
with an antigen and are not limited to targeting only tumors that have a specific marker as in
CAR-T methods [62].
Clinical studies for ovarian and breast cancer using IV delivered NK cells enriched by
CD3 depletion of PBMCs from haploidentical donors failed to show in vivo NK cell expansion
perhaps due to suppression by host Treg cells or myeloid-derived suppressor cells (MDSCs)
[42]. Therefore, there is still an insufficient understanding about factors required for NK cell
expansion and in vivo persistence for successful clinical outcome. A previous pre-clinical study
showed that IP delivered enriched NK cells could have anti-tumor response against ovarian
cancer, and that NK cell cytotoxicity may be affected by the mode of delivery that could bypass
hurdles of NK cell homing to the tumor location [63].
The quality of immune response to ovarian cancer has a significant impact on disease
prognosis [64-66]. In the context of a complete immune system, innate NK cells can have direct
cytotoxicity towards transformed cells as well as interact with DCs to induce interferon IFN-γ
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production which primes Th1 cells [67] and further enhances cytotoxic T cell responses [68]. NK
cells are indispensable for effective DC-based immunotherapy, as loss of NK cells has shown to
result in defective tumor immunity [69]. Such studies highlight the importance of NK cell
interactions with both, innate and adaptive immune cell types, to affect adaptive immunity for
effective anti-tumor response.
Here, we examine NK and T cells’ response to tumor as part of an unbiased whole
PBMC population as opposed to treating with selectively enriched NK or T cell populations. The
study examines the kinetics of effector subtypes involved in the acute anti-tumor response of
innate and adaptive components of PBMCs and identifies NK cells as the main effector cell of
PBMCs’ response, acting as a first line of anti-tumor defense. It also highlights the importance
and points to the need for further studies to delineate other interacting immune cell types to
strategically employ them as an adjuvant regimen for a safe and effective NK cell-based
immunotherapeutic approach.
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Materials & Methods
Animals
Animal care and use was at the Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC)-accredited University of Central Florida
(UCF) vivarium. Protocols were approved by the UCF Institutional Animal Care and Use
Committee (IACUC) and were compliant with NIH guidelines. NOD.Cg-Prkdcscid Il2rγtm1Wjl/SzJ
(NSG) mice were obtained through an institutional material transfer agreement with Jackson
Laboratory, Bar Harbor, Maine, USA.
Human Ovarian Tumor Cells and Engraftment in Mice
Human ovarian tumor cell line SKOV-3/GFP-Luc was obtained from Cell BioLabs, Inc.
(San Diego, CA, USA). The cell line was passaged in an NSG mouse once, then sorted for green
fluorescent protein (GFP) expressing tumor cells using a cell sorter (FACSAria), BD
Biosciences, Franklin Lakes, NJ, USA). NSG mice were IP injected with 1x106 SKOV-3GFP/Luc cells and tumors seeded for 7-10 days. Tumor growth was monitored by in vivo
bioluminescent imaging.
In vivo Imaging
SKOV-3/GFP-Luc tumor formation and growth was monitored using the Xenogen In
vivo Imaging System (IVIS, Caliper Life Sciences, Hopkinton, MA, USA). Luciferin (Gold
Biotechnology, Inc., St. Louis, MO, USA,) was IP injected at a dose of 0.15mg/g body weight
fifteen minutes prior to imaging. Maximum/minimum of the luminescence signal intensity was
adjusted to be the same throughout the experiment (Living Image software, Perkin Elmer,
Waltham, MA, USA).
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Human PBMCs
Human PBMCs were obtained from healthy human donor source leukocytes (OneBlood,
Orlando, FL, USA) by standard Ficoll gradient. Isolated PBMCs were tested for viability using
Annexin V staining and NK cell percentages by flow cytometry using a BD Accuri C6, BD
Biosciences, San Jose, CA, USA) following staining by CD45, CD3 and CD56 antibodies. The
initial NK cell percentages for PBMCs used in the experiments were 8-11% of total CD45+ cells.
After tumor engraftment (7-10 days after inoculation), 1 x 106 viable PBMCs and 1,000U human
IL-2 (Preprotech, Rocky Hill, NJ, USA) were IP injected. 1,000U IL-2 injections were given to
mice weekly on Monday, Wednesday and Friday throughout the experiments.
Flow Cytometry
Fifteen minutes after subcutaneous saline injections to hydrate the animals, <100 μL of
peripheral mouse blood was collected by submandibular bleeds once a week. 50 μL of blood was
treated with red blood cell lysis buffer and stained with fluorophore conjugated antibodies
against hCD45 (eBiosciences, San Diego, CA, USA), hCD56 (Miltenyi Biotec, Bergisch
Gladbach, Germany) and hCD3 (Beckman Coulter, Brea, CA, USA). Peritoneal washes obtained
by flushing ~2mL PBS in the peritoneal cavity were also processed similarly. Analysis of the
data was done using the software Flowlogic (Inivai Technologies, Victoria, Australia). All NK
cells (CD56+, CD3-) were first gated on human CD45+ cells.
Histology
Tumors were fixed in 10% neutral-buffered formalin (Surgipath, Leica, Buffalo Grove,
IL). Tissue was processed, embedded in paraffin blocks and 5 μm sections were stained.
Immunohistochemistry (IHC) was done using Leica’s BondMax automated immunostainer.
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Antibodies included NKG2D (GeneTex, Inc., Irvine, CA, USA). Granzyme B (Spring
Bioscience, Pleasanton, CA, USA), Cleaved Caspase 3 (Cell Signaling Technology, Inc.,
Danvers, MA, USA), CD3 (Abcam Cambridge, MA, USA).
Granzyme Assay
From the tumors of mice treated for 14 days with PBMCs, cells were perfused using 18
gauge needles. They were washed and incubated with SKOV-3/GFP-Luc cells (50,000/well) on a
96-well plate for 1 hour. Cells were stained with anti-CD45, -CD3 and -CD56 antibodies in a
granzyme substrate (PanToxiLux kit; Oncolmmunin, Gaithersburg, MD, USA). After 30min
incubation with antibodies, samples were analyzed by flow cytometry (CantoII, BD Biosciences)
and analyzed using Flowlogic software. To analyze the granzyme substrate signal (Fluorescein
isothiocyanate, FITC) in the background fluorescence from the endogenous GFP of SKOV3/GFP-Luc cells present in the NK cell (or T cell)-SKOV-3/GFP-Luc conjugates, a sample
without granzyme substrate was used to define the fluorescent intensity for events correlating to
cells that lack granzyme activity (Figure 4b).
Cytotoxicity Assay
SKOV-3/GFP-Luc cells were plated on a 96-well plate at 10,000 cells/well and incubated
overnight at 37C. NK cells (EasySep human NK cell enrichment kit, Stem Cell Technologies
Inc., Vancouver, BC, Canada) were stimulated with 100 U IL-2 overnight and then incubated
with plated tumor cells at different Effector (NK cells) : Target (tumor cells) ratios (E:T) for 48
hours. Cytotoxicity was measured using the CytotoxGlo assay (Promega Corp., Madison, WI,
USA) as per manufacturer’s instructions.
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Results
Treatment with unselected healthy PBMCs clears human ovarian tumors engrafted in mice.
The interplay among multiple immune cell types in response to the presence of a tumor is
complex and is still poorly understood. To address the therapeutic effectiveness of unselected
immune cells from normal donor PBMCs in response to the presence of tumor, NSG mice that
were IP inoculated with 1 x 106 SKOV-3/GFP-Luc cells were monitored for engraftment. Mice
that showed engraftment 7 days post inoculation were then treated with PBS as a control, low
dose IL-2 only (1,000 U thrice weekly), or with human PBMC+IL-2. Another group of nontumor bearing mice was injected with PBMC+IL-2 as a control. Treatment effectiveness was
assessed by monitoring tumor size and overall health for 7 weeks after starting treatments. Serial
imaging (Figure 1a) shows significant differences in tumor progression between the mice
injected with PBS or IL-2 only (‘untreated’ group) and the ‘PBMC+IL-2 treated’ group.
Untreated mice succumbed to disease in ~3 weeks, whereas tumor-engrafted mice treated with
PBMC+IL-2 showed reducing tumor burden. Figure 1a shows reduction of tumor size in the
treated group and total luminescence flux from the peritoneal tumor images acquired after
PBMC injections (Figure 1b) also demonstrates the effect of treatment compared with no
treatment (p=0.0003, two-way ANOVA). A clear survival difference was observed in PBMCtreated compared to untreated mice (p=0.001, Log-rank Test) (Figure 1c). Untreated mice were
euthanized upon health deterioration including abdominal bloating due to ascites and hunched
posture. Overall, tumor-engrafted mice treated IP with whole PBMCs showed tumor regression
within 3 weeks of PBMC treatment as compared to the untreated mice that succumbed to the
disease within the same time frame.
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Expansion of NK cells in peripheral blood and peritoneal cavity of PBMC treated tumorengrafted mice
To determine if the cytolytic effector components in the anti-tumor response with the
PBMC+IL-2 treatment is due to a single or synergistic lymphocyte populations in the allografted
PBMCs, levels of immune cells were serially tracked in mouse peripheral blood for up to 7
weeks after PBMC injection. Delivering unselected healthy donor PBMCs along with low-dose
IL-2, the expansion of NK cells was observed in the blood of only mice seeded with tumor.
Also, mice that were injected only with PBMCs+IL-2 but without any tumor, showed no
engraftment of NK cells (Figure 2). In a subsequent experiment, sets of mice treated with
PBMC+IL-2 were collected on days 7, 14 and 21 post-treatment to examine the human
lymphocyte population and their interaction with the tumor in the intraperitoneal cavity (Figure
3). Similar to the previous experiment, treatment of tumor-seeded mice with PBMC and IL-2
delivered IP resulted in reduced tumor and complete clearance by 21 days after initiation of
treatment. For each of the mice sacrificed on days 7, 14 and 21, cells were collected from the
intraperitoneal cavity and were analyzed by flow cytometry. As seen previously in the analysis
of peripheral blood, NK cell expansion occurred only in the presence of tumor, and despite IL-2
stimulation, mice without any tumor did not show NK cell engraftment, expansion or
persistence. NK cell number peaked at day 14, when tumor signal intensity was also at its peak
(Figure 1b) and then started to decline as the tumor regressed. Data from the blood analyzed
during this experiment is shown in Supplemental Figure 1 with a similar trend as seen in the
blood analysis of the survival experiment (Figure 2). These results show that the presence of
tumor elicits specific expansion of NK cells from an unselected PBMC population, in the
presence of low dose IL-2.
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NK cells infiltrate tumor and show markers of cytotoxicity
To corroborate that NK cell expansion in the presence of tumor in vivo and subsequent
tumor remission was due to NK cell mediated cytotoxicity, shrinking tumors were collected from
14 day treated mice and from untreated mice for analysis by histology. NKG2D was used as an
NK cell marker because it is one of the main activating receptors on NK cells that recognizes
various stress induced ligands on tumor cells (22). Staining of a tumor nodule section (Day 14
after PBMC inoculation) from the PBMC+IL-2 treated group with anti-NKG2D showed positive
NKG2D staining (Figure 4), which is indicative of intratumoral infiltration of NK cells.
Granzyme release was observed in the same region of the tumor. This is consistent with the
presence of granzyme containing cytotoxic granules released from NK cells upon tumor cell
recognition to mediate apoptosis by caspase dependent pathways [70]. Detection of cleaved
caspase 3 by staining in the same region as that of granzyme release confirms NK cell induced
apoptosis of tumor cells (Figure 4).
Since T cell expansion was observed in the peripheral blood (Supplemental Figure 2) and
the peritoneal cavity (Supplemental Figure 3), their presence was also examined by staining with
anti-CD3. CD3 staining was minimal (last panel in Figure 4) as compared to NKG2D staining in
the same region of the tumor or as compared to CD3 staining in a human lymph node used as a
positive control, thus confirming that the cytotoxicity markers were attributable to infiltrating
NK cells killing tumors cells and not T cells. The NKG2D staining appears to be dim in the
region shown, perhaps because of actively dying cells in that area due to granzyme release. A
different region of the tumor shows clearer NKG2D staining (Supplemental Figure 4). These
results indicate that NK cells expand in the vicinity of the tumors (peritoneal cavity) and
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infiltrate into the small tumor nodules to cause tumor regression observed in the PBMC+IL-2
treated mice.
NK cells show direct cytotoxicity towards tumor cells ex vivo
A cytotoxicity assay (CytotoxGlo) was done with enriched NK cells from the same
PBMC source as used in the experiment shown in figure 3 to show that NK cells present in the
PBMC source were cytotoxic towards the tumor cells. Reducing cytotoxicity of tumor cells was
seen with decreasing E:T ratios (figure 6). To confirm that the intratumoral NK cells were also
cytotoxic and not anergic, intratumoral perfusions were isolated from two tumor bearing mice
being treated with PBMCs+IL-2 for 14 days and were tested for granzyme activity as discussed
in the methods section. Flow cytometric analysis of granzyme activity in singlet vs. doublet
tumor-lymphocyte conjugate populations was performed as previously described [71], to
determine the cytotoxic response of intratumoral NK and T cells against fresh SKOV-3/GFP-Luc
cells (Figure 13). Differences in scatter properties (forward scatter height vs area plots) and
CD45 intensity were used to determine the conjugates (tumor cells and immune cells) and singlet
cell populations. Populations were further gated for CD56+, CD3- NK cells and CD3+ T cells,
and for signal from granzyme activity. Figure 5 represents the events positive for granzyme
activity seen in singlet and conjugate cells. Overall, significant difference (p=0.0002, two-way
ANOVA) was observed in the number of granzyme-positive NK cells as compared to T cells
with majority of the NK cells forming conjugates with tumor cells. These results show that
isolated intratumoral NK cells are not anergic and highly cytotoxic towards SKOV-3/GFP-Luc
tumor cells, and gives strong evidence that the tumor shrinkage effect observed in vivo is due to
cytolytic activity from NK cells and not T cells.
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Whole PBMC treatment results in longer survival as compared to treatment with PBMCs
depleted of one or more cell types
In order to show that the cytotoxicity against tumor and overall survival of tumor bearing
animals is optimal when they are treated with NK cells as a part of the whole PBMC population,
an experiment was set up in which mice inoculated with the tumor cells for a week were treated
with isolated NK cells, NK cell depleted PBMCs and T cell depleted PBMCs. All mice received
1000 U of IL-2 IP, thrice a week for the entire length of the study. Figure 7a shows in vivo
imaging of all the animals over 7 weeks after the start of treatment (Day 0). Untreated mice
started to decline in health in the third week after the start of treatments. ‘Isolated NK cell
treated’ group as well as the ‘T cell depleted PBMCs’ group also started to decline in health
because of growing tumors and no expansion of lymphocytes, as seen in figure 8. This was
perhaps due to the lack of sustained IL-2 supply form T cells necessary for NK cell to thrive, in
addition to low-dose IL-2 provided exogenously. On the other hand, mice in the whole ‘PBMC
treated’ group and the ‘NK cell depleted PBMCs treated’ group showed extended survival, as
shown in figure 7b. Even though, mice in both of these groups showed tumor remission, mice in
the NK cell depleted PBMCs treatment group showed signs of GVHD. Mice appeared to be
suffering from diarrhea and eventually became lethargic and weak before they died or were
euthanized because of severely declining health condition. Mice in the whole PBMC treated
group however, survived longer but ultimately succumbed to GVHD phenotypes a week later.
Figure 8 shows data obtained from weekly blood analysis done using flow cytometry. Mice in
the PBMC treated group show high NK cell numbers on day 14, which is consistent with the
earlier experiments that showed NK cells to be the cytotoxic population. Mice treated with NK
cell depleted PBMCs do not show any NK cells (as expected), but show expansion of NKT cells
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and T cells. Perhaps, the tumor clearance in this group of animals despite the absence of NK
cells could be attributed to these cell types. However, after tumor clearance, high number of T
cells in this group (day 28) contributed to GVHD-like symptoms and ultimately caused death
whereas PBMC treated animals who had relatively low number of T cells survived for another
week. In conclusion, overall health with respect to the tumor and GVHD symptoms, was found
to be best in PBMC treated mice amongst the conditions tested here.
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Figures
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Figure 1: SKOV-3/GFP-Luc tumor bearing mice show complete remission of tumor upon healthy human PBMC and IL-2 treatment.
a) Bioluminescence of representative mice showing SKOV-3/GFP-Luc tumor burden over 7 weeks. Mice shown in the left panel were
untreated (PBS or IL-2 only), whereas the ones in the right panel were treated with PBMCs+IL-2 and monitored for tumor growth. b)
Quantification of the tumor signal (total flux) obtained from imaging. P-value was <0.001 for the first three time-points (two-way ANOVA,
GraphPad Prism). c) Curve showing the difference in overall survival of the untreated and PBMC treated mice from the day of tumor cell
inoculation. p= 0.001 (Log-rank test, GraphPad Prism).
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Figure 2: NK cells increase in peripheral blood in response to the presence of engrafted tumor.
Plots show the fraction of human lymphocytes (left) and concentration (right) of human CD45+, CD56+, CD3- NK cells in mouse peripheral
blood at the indicated number of days after initiation of treatment. p=0.005 (left); p= 0.009 (right) (two-way ANOVA, GraphPad Prism).
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Figure 3: NK cells from whole PBMCs expand in the presence of tumor within the peritoneal cavity.
a) After 10 days of SKOV-3/GFP-Luc engraftment, 3 groups were treated with 1x106 human PBMC+IL-2. Five mice were euthanized every
week for 3 weeks for the analysis of peritoneal cavity wash. Another 3 groups of mice (not shown here) with no tumor and injected only with
PBMCs+IL-2 were also collected along with the tumor bearing mice, as controls. b) Plots show the trend of expansion and reduction of NK
cells in the peritoneal cavity expressed as fraction of human lymphocytes (left) and as concentration (right) over a time period of 3 weeks.
p=0.0001(left); p=0.0052 (right) (two-way ANOVA, GraphPad Prism).
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Figure 4: In vivo expanded NK cells infiltrate tumors and mediate tumor killing.
The left panel shows representative images of a tumor nodule from the ‘untreated’ group of animals; the right panel shows that of ‘PBMC+IL2 treated’ ones. The H&E image in the top panel shows infiltrating immune cells compared to the untreated tumor. Tumor cells have Ki67
staining indicating proliferation. NKG2D staining shows NK cells within the tumor of the PBMC+IL-2 treated group. Granzyme B staining
shows NK cell granules containing granzyme which mediate target cell lysis. Cleaved Caspase 3 staining indicates apoptosis in the tumor
cells. The last panel shows the lack of CD3 staining in the same region of the tumor showing apoptosis. A human lymph node (LN) is shown
as a positive control for the human CD3 antibody. All images were acquired using a 40X objective and scale bars represent a length of 50µm.
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Figure 5: Granzyme assay showing actively cytotoxic NK cells perfused from tumors.
Graph representing granzyme positive events of NK and T cells present in CD45 + singlet or conjugated
populations upon perfusion from tumors. p=0.0002 (two-way ANOVA).
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Figure 6: Cytotoxicity against SKOV-3/GFP-Luc is NK cell dependent.
Graph showing %cytotoxicity by isolated NK cells (effector) in SKOV-3/GFP-Luc (target) cells at
different effector : target (E:T) ratios. Decreasing number of NK cells against the same number of tumor
cells shows a decreasing trend in cytotoxicity.
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Figure 7: Survival difference between the untreated group and groups treated with PBMCs or PBMCs
depleted with different cell types.
a) Bioluminescence images of mice showing SKOV-3/GFP-Luc tumor burden (seeded for 7 days) over 5
weeks from the start of treatment. Mice shown in the panels from left were, untreated, treated with whole
PBMCs, treated with isolated NK cells, treated with PBMCs depleted of NK cells and treated with
PBMCs depleted of T cells. All mice were injected with 1000 U IL-2 thrice a week. b) Survival curve
showing the difference in overall survival between different groups from the day of tumor cell
inoculation. p= 0.002 (Log-rank test, GraphPad Prism).
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Figure 8: Expansion of peripheral blood cell types in different groups.
Plots showing total lymphocytes, NK cells, NKT cells and T cells per mL in mouse peripheral blood at
the indicated number of days after initiation of treatment in different groups.
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Figure 9: Supplemental Figure 1.
Plots showing NK cell expansion and reduction expressed as a fraction (left) and as concentration (right), in peripheral blood. These were
analyzed parallel to the data shown in Figure 3. p=0.07 (left); p=0.0001 (right) (two-way ANOVA).
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Figure 10: Supplemental Figure 2.
Plots showing T cells in the peripheral blood over time in tumor bearing and non-tumor bearing mice treated with PBMC+IL-2, as a fraction
(left) and as concentration (right). This data is from the survival experiment shown in Figure 1. p=0.01 (left); p=0.06 (right) (two-way
ANOVA).
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Figure 11: Supplemental Figure 3.
Plots showing T cells in the peritoneal wash over time in tumor bearing and non-tumor bearing mice treated with PBMC+IL-2. This data is
from the experiment shown in Figure 3. p=0.02 (left); p=0.01 (right) (two-way ANOVA).
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Figure 12: Supplemental Figure 4.
IHC images showing NKG2D staining in untreated and PBMC +IL-2 treated tumor tissue, indicating
infiltration of NK cells into the tumors.
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Figure 13: Supplemental Figure 5.
Schematic of the gating strategy for the granzyme activity assay shown in Figure 5. First panel (left) shows the two distinct CD45+
populations, conjugates and singlets. In the second panel, FSC-H vs FSC-A plots for both populations are represented as overlays show
conjugate formation. Third panel shows gating of the two populations for CD56 and CD3. The last panel shows granzyme activity positive
events gated on the NK cell population.
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Discussion
In this study, complete tumor remission and increased survival of tumor bearing NSG
mice was observed when mice were treated with healthy donor derived PBMCs, as compared to
the untreated ones. From the whole PBMC population injected, NK cell expansion was observed
in the peritoneal cavity as well as in the peripheral blood of the tumor bearing mice, whereas no
immune cell expansion or NK cell engraftment was seen in the control mice without any tumor.
There was also a correlation between tumor shrinkage and decreasing number of NK cells in the
treated mice. Importantly, flow cytometry of granzyme activity of immune cells isolated from
tumors showed that 1) there were more NK cells than T cells, 2) the majority of tumor
conjugates were that of tumor-NK cells and 3) these tumor-NK cell conjugates had granzyme
activity. These data collectively led us to conclude that NK cells were the effector cells
responsible for the tumor regression and progression-free survival of the mice.
Previous studies with either allogeneic or autologous NK cell adoptive therapy have been
inconsistent in producing successful clinical outcomes due to various reasons, most importantly
the inability of NK cells to expand and persist in vivo [44]. A phase II study with IV delivered
haploidentical NK cells in ovarian and breast cancer patients with recurrent disease following
lymphodepleting chemotherapy showed sub-optimal NK cell expansion [42]. Another study with
adoptively transferred autologous NK cells showed proliferation and persistence in vivo, but the
NK cells failed to exhibit cytotoxicity due to immunosuppression without any overall benefit to
the health of the patients [72]. A study in a xenograft mouse model showed progress with in vivo
persistence of NK cells by changing the mode of delivery from IV to IP, but this study required
very high starting dose of in vitro IL-2 pre-activated NK cells (20x106), enriched by T and B cell
depletions of PBMCs, and high dose IL-2 (75,000 U/day IP daily for 3 weeks) in order to allow
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reduction in tumor burden [63]. In contrast, only 1 x 106 whole PBMCs (8-11% NK cells) were
injected IP along with very low dose of IL-2 (1,000 U thrice weekly) to induce complete tumor
remission in this study. This suggests that a supportive or synergistic role of other cell types in
the whole PBMC population is crucial for optimal NK cell cytotoxic activity against tumors.
Cell types that are known to augment NK cell proliferation and maintenance are
monocytes, DCs and T cells. Monocytes have been shown to aid in NK cell expansion mediated
by some soluble factors [73]. Results from in vitro and clinical studies indicate that cytokines
such as IL-2, 1L-12 and IL-21 enhance NK cell proliferation and effector functions such as IFNγ secretion [74, 75]. DCs also play a role in NK cell effector functions like IFN-γ production and
cytolytic activity in vitro [76, 77]. Mouse and human studies show that they mediate their
support mainly through secretion of IL-12 [78, 79] and trans-presentation of membrane bound
IL-15 on mature DCs [76, 80-82]. In addition to triggering NK cell expansion and activation
through a direct cell-to-cell contact, DCs can also influence NK cells by releasing exosomes [83,
84]. A clinical study showed that vaccination with dendritic cell derived exosomes harboring
NKG2D ligands and functional IL-15Rα, synergize for NK cell proliferation and activation in
vitro and in patients [85]. In addition to monocytes and DCs, NK cells are also dependent on
activated CD4+ T cells for the availability of IL-2. In our study, the presence of T cells in the
peritoneal cavity (Figure 11) may have provided IL-2 for NK cell expansion in addition to lowdose exogenous IL-2. Data from figures 7 and 8 supports this and clearly shows the dependence
of NK cells on T cells because, treatment with isolated NK cells did not lead to expansion in
vivo. Secretion of IL-2 by these cells also causes Treg cell expansion as a negative feedback to
prevent overstimulation of CD4+ T cells. Therefore, Tregs restrict the availability of IL-2 for NK
cells causing suppression of NK cell expansion and activity [86, 87], thus validating the effect of
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Treg depletion to enhance tumor suppression by NK cells [88, 89]. In our study, the presence of
T cells in the peritoneal cavity (Figure 11) may have provided IL-2 for NK cell expansion in
addition to low-dose exogenous IL-2. Apart from indirect inhibition of NK cells, Tregs can also
directly suppress NK cells in a tumor microenvironment by secreting TGF-β, which is known to
suppress NKG2D expression on NK cells and mitigate tumor cell lysis [34]. From these
examples, it is clear that cross talk of NK cells with different components of the PBMCs plays a
critical role in the regulation of NK cell proliferation and function.
In addition to being regulated by different components of PBMCs, NK cells are also
involved in maintaining fine balances in immune responses, specially contributing towards
prevention of GVHD. Secretion of IL-2 by T cells can also cause an abundance of T cells that
may lead to GVHD. NK cells are known to inhibit T cells in such a case and reduce GVHD by
increasing apoptosis in T cells [90, 91]. The experiment shown in figure 7 and 8 supports this
and shows that in the group treated with NK depleted PBMCs, animals succumbed to GVHD
symptoms, whereas the PBMC treated group showed a delay in GVHD symptoms, perhaps after
NK cell numbers waned down after day 14.
In our study, NK cells infiltrated into small diffuse tumor nodules in the peritoneal cavity
and were able to degranulate to induce cytotoxicity. This models residual tumor burden or
diffuse persistent ovarian carcinoma where tumor sizes are small and perhaps not as
immunosuppressive as compared to an advanced tumor. For the treatment of advanced tumors,
NK cell therapy in combination with other treatment modalities may be required to achieve
maximal clinical benefit. Various types of combination immunotherapies have been carried out
in ovarian carcinoma patients, with promising results [18]. A new clinical trial is recruiting
patients with recurrent ovarian and fallopian tube cancer along with other primary peritoneal
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carcinomas, for a phase1 study looking at the effect of in vivo suppression of T cells by using an
indoleamine 2,3-dioxygenase (IDO) inhibitor, along with IP delivery of haploidentical NK cells
(Clinicaltrials.gov identifier: NCT02118285). IDO is prevalent in ~56% of ovarian carcinomas
and is associated with an immunosuppressive tumor microenvironment [92]. Also, in the ID8VEGF ovarian carcinoma mouse model, decreased proliferation and the inability of the tumor
infiltrating lymphocytes to produce cytokines was attributed to the expression of CTLA-4 and
PD-1 makers [93]. Therefore, a combination of NK cell therapy with other strategies such as
checkpoint inhibition may result in better clinical responses. For HLA expressing tumors that are
resistant to NK cell lysis, combining NK cell therapy with an anti-KIR receptor antibody may be
useful [94]. Because of the heterogeneous nature of tumors and a myriad of escape mechanisms
used by tumors to evade the immune system, combining different approaches that inhibit
mechanisms for immune escape in eclectic combinations is a rational approach.
NK cell function is regulated by a balance between various combinations of activating
and inhibitory signals that allow the diversity of NK cell repertoire in an individual, but the link
between NK cell diversity and NK cell function is only starting to be understood. In an analysis
of peripheral blood NK cells, a study showed that there are 6-30,000 phenotypic variants of NK
cells in an individual [95]. While inhibitory receptor expression is largely genetically governed,
activation receptors are influenced by environmental factors in an individual [95]. The whole
PBMC approach in our study rather than using enriched, in vitro IL-2 pre-activated NK cells,
likely resulted in the conservation of the diversity of the activated NK cell repertoire due
intercellular stimulation of NK cells with other components of the healthy donor PBMC
population and tumor. This may have contributed to effectiveness of tumor induced NK cell
expansion in vivo from low starting percentages (8-11%) to ~20% NK cells in the total
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lymphocyte population, and stimulation of anti-tumor efficacy. In adoptive transfer of isolated,
pre-activated NK cells, the lack of intercellular stimulation from other lymphocyte types and
potentially skewing of NK cells during in vitro pre-activation may possibly account for the lack
of NK cell expansion and anti-tumor efficacy in ovarian carcinoma patients. For an effective
anti-tumor response, all components are likely to have a role, but the absence of NK cells has
shown to impair tumor rejection [96].
Results from these studies suggest that the cross talk of NK cells with other cell types in
the PBMC population may be responsible for NK cell proliferation, infiltration into small and
diffuse tumors and anti-tumor cytotoxicity. This may be an important consideration for utilizing
NK cell-based immunotherapy as an adjuvant after surgical tumor resection and frontline
chemotherapy, especially in case of tumors where the elimination of residual tumor could be
very significant to prevent relapse, such as in ovarian cancer treatment. Therefore, this study
provides a proof-of-principle for the therapeutic potential of NK cells in the anti-tumor response
and highlights the importance of further investigating cell-to-cell interactions within PBMC
population, based on which, different combination approaches could be designed to significantly
attenuate tumor evasion.
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CHAPTER 3: NK CELLS STIMULATED WITH PM21 PARTICLES
EXPAND AND BIODISTRIBUTE IN VIVO: CLINICAL IMPLICATIONS
FOR CANCER TREATMENT
Introduction
Natural killer (NK) cells are a component of the innate immune system, identified by
being CD56+CD3-, and can naturally recognize and lyse cells that are virally compromised or are
malignant. Cell therapy with NK cells is promising as a cancer treatment and multiple clinical
trials have been conducted and are currently underway for treatment of various cancers (AML,
lymphoma, non-Hodgkin lymphoma, breast, ovarian, neuroblastoma, non-small cell lung
carcinomas). For effective anti-cancer therapy with NK cells, three general aspects must be
considered: 1) a large enough dose of NK cells must be delivered; 2) NK cells must be highly
cytotoxic; and 3) NK cells must reach, possibly localize at the site of disease, persist and
specifically target tumor cells [97].
For clinical efficacy in an AML setting, Miller and co-workers have recommended
attaining a dose that would provide at least 100 NK cells per µL of peripheral blood (PB) at two
weeks post infusion [98]. In some examples where treatment with adoptive NK cell therapy was
efficacious, over 1,000 NK cells per µL of PB were observed. These observations highlight the
importance of proficient NK cell expansion methods for delivery of a sufficient dose for overall
treatment efficacy.
Currently, there are broadly three different clinically used strategies for NK cell
expansion for adoptive cell therapy. First, in vivo expansion with cytokines such as IL-15 and IL2, combined with host lymphodepletion/irradiation, may stimulate in vivo expansion from the
relatively low amount of injected donor NK cells [39, 99, 100]. Second, ex vivo methods with
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cytokines, mainly using IL-2 and IL-15 [101], can activate NK cells, although expansion is
relatively low and variable. Also, NK cells activated ex vivo with cytokines undergo cytokine
withdrawal after infusion and the NK cells undergo apoptosis [102, 103]. Third, feeder cell
methods for ex vivo NK cell expansion use co-cultures with other cells that are stimulatory.
Feeder cell methods for NK cell stimulation include Epstein-Barr virus-Lymphoblastoid cell
lines [45, 104], or engineered tumor cells. Co-culture with K562 leukemia cells expressing
membrane bound IL-15 (mb15) and 4-1BB ligand (41BBL) (K562-mb15-41BBL) are able to
expand NK cells several hundred fold in about two weeks, but the NK cells expanded by this
method experience senescence [47, 49]. In addition, NK cells activated with IL-15 lose surface
CD16 by proteolytic activity of ADAM17 [105]. Rather K562 cells expressing mb21 (focus of
this study), instead of mb15, significantly improves NK cell expansion while avoiding telomere
shortening and consequent NK cell senescence [49, 106]. Expansion of NK cells with the K562mb21-41BBL is very efficient and a mean 48,000-fold expansion with >85% enrichment is
typically achieved in three weeks [49]. All of these methods are actively being investigated in
clinical trials.
While NK cell expansion methods have improved, there are still disadvantages and
challenges. To date, highly toxic doses of IL-2 are required regardless of expansion method for
survival of the infused NK cells, and the persistence of the NK cells is still limited. While ex vivo
methods with feeder cells have been effective for expansion to generate large amounts of NK
cells, concerns have been raised that long term ex vivo culturing of NK cells causes loss of ability
to home to the site of disease such as bone marrow [107]. Thus, there has been a debate about the
overall benefits of in vivo vs. ex vivo expansion [108]. An optimal NK cell expansion procedure
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would be a method which has the proliferation capability of an ex vivo feeder cell based method,
but could be performed either ex vivo or in vivo.
Recently, a novel particle based method for rapid and selective expansion of cytotoxic
NK cells starting with PBMCs was reported [48]. In this report, the particles corresponding to
closed plasma membrane vesicles were prepared from plasma membrane of K562-mb15-41BBL
cells (PM15-particles) and allowed selective NK cell expansion of 250-fold in 14 days and
1,265-fold after 17 days, which is comparable to the expansion efficiency using K562-mb1541BBL feeder cells in co-culture. PM15-particle activated NK cells, similar to feeder cell
expanded NK cells, were highly cytotoxic towards leukemia cells ex vivo. Importantly, these
particles offer many advantages over the currently used feeder cell methods. First, they can be
prepared in advance, tested and stored for more than a year and can be used as an “off-the-shelf
reagent” to simplify the clinical logistics. Second, use of the PM-particles, instead of feeder cells
to stimulate NK cells, eliminates steps needed for safety measures when using tumor-derived
feeder cell such as feeder irradiation and testing their presence and proliferation in the final
product. Third, tumor-derived feeder cells cannot be injected as an adjuvant therapy whereas the
PM-particles are injectable to stimulate in vivo expansion of NK cells. The advantages offered by
the PM-particle based method for NK cell expansion would likely allow for significant clinical
benefits.
Here in this work, we test the efficacy of PM-particles prepared from K562-mb2141BBL for in vivo expansion of adoptively transferred NK cells, pre-activated with a relatively
short and simple procedure that could be easily implemented in a clinical setting. The method
overcomes the shortcomings of previous studies with IV infusion of adoptive NK cells that only
allowed very minimal in vivo NK cell expansion and had limited persistence. For the current
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study, efficacy is shown for PM21-particle stimulated ex vivo and in vivo expansion of NK cells
from unselected PBMCs injected into the peritoneal cavity, which is intended to serve as site for
incubation and stimulation by PM21-particles. This method is expected to be useful for the in
vivo expansion of NK cells at therapeutically relevant amounts and presents means to make NK
cell-mediated immunotherapy more widely accessible to patients.
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Materials & Methods
Human Samples
Leukocyte source (One Blood, Orlando, FL) or fresh blood collected from healthy
volunteers who signed and IRB approved informed consent were used as healthy samples.
Primary leukemia blasts were obtained from patients, who signed an IRB-approved informed
consent, during active disease and comparable PB was collected from these patients during
remission. PBMCs were isolated using Ficoll-Paque (GE Healthcare, Pittsburgh, PA) as
previously described [48]. All samples were de-identified and viably cryopreserved.
Reagents and Cell Lines
K562 cell line was obtained from ATCC (Manassas, VA). K562-mb15-41BBL was
kindly provided by Dr. Dario Campana (St. Jude Children’s Research Hospital, Memphis, TN).
Annexin-V FITC kit for cytotoxicity assays and Enumeration Flow-Count beads purchased from
Beckman Coulter (Miami, FL). The following dye conjugated antibodies were used for
phenotyping: CD16-FITC, NKG2A-PE, NKp46-PE, CD3-APC (Beckman Coulter); CD4-APCCy7, CD8-PE, CD56-BV421, CD94-APC (BD Biosciences); CD3-Alexa488, NKG2D-APC,
CD62L-PE-Cy7, CD45-eFluor450, CD45-APC (eBiosciences); CD56-PE, KIR2D-APC
(Miltenyi); NKG2C-PE NKp44-APC, TRAIL-PE (R&D Systems).
Preparation And Characterization Of Plasma Membrane Particles
PM-particles were prepared from K562-mb15-41BBL or K562-mb21-41BBL cells as
previously described [48]. PM-particle preparations were quantified by protein concentration by
BCA assay and specified as g of membrane protein/mL. Presence of IL-21 and 41BBL on PMparticles was confirmed by ELISA and Western Blot.
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Ex Vivo NK Cell Expansion From PBMCs
NK cells from PBMCs were expanded using PM21-particles as previously described
[48]. Briefly, PBMCs were seeded at 0.1 x 106 NK cells/mL in SCGM (CellGenix, Portsmouth,
NH) supplemented with 10% FBS, 2 mM Glutamax, 100 U/mL IL-2 (Peprotech, Rocky Hill, NJ)
and 200 µg/mL PM21-particles. Media with supplements was replaced routinely every 2-3 days
after day 5.
In Vivo Expansion of NK Cells in NSG Mice
PBMCs, either freshly thawed or pre-activated for two days with 200 µg/mL PM21 and
100 U/mL IL-2, were washed twice and resuspended in phenol red-free RPMI media. 1 x 105 NK
cells in a whole PBMC cell suspension were injected IP into NSG mice. PM21-particles
(amounts specified in figure legends, twice weekly) and IL-2 (1,000 U, thrice weekly) were also
injected IP and PB was collected by cheek bleeds or cardiac puncture. Organs were collected at
necropsy were perfused to obtain single cell suspensions for analysis.
In Vivo Proliferation Analysis
PBMCs, freshly thawed or pre-activated with PM21-particles and 100 U/mL IL-2 for two
days (PM21-PBMCs) were labeled with Cell Trace (CT) Violet (Invitrogen, Carlsbad, CA).
2x106 non pre-activated PBMCs and PM21-PBMCs were injected IP to NSG mice. Mice in all
groups received 1,000 U IL-2, IP, thrice weekly. Two of the groups of mice were also injected
with 400 µg of PM21-particles, IP, twice weekly. Mice from each group were euthanized on day
6 and the peritoneal wash was analyzed by flow cytometry for CT violet fluorescence of CD45+,
CD3-, CD56+ NK cells. Peritoneal wash was collected by making a small incision in the
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peritoneum immediately after euthanizing the mice and flushing PBS in the cavity a few times
using a pasteur pipette.
In Vivo PM21 Titration
PBMCs were pre-activated ex vivo with PM21-particles and 100 U/mL IL-2 for 2 days.
PM21-PBMCs in the amount containing 0.2 x 106 of viable NK cells were injected IP to NSG
mice. Mice in all groups received 1,000 U of IL-2, IP thrice weekly. Mice were also injected
with 0, 400, 800, 1,600 µg of PM21-particles, IP twice weekly. Peripheral blood was analyzed
by flow cytometry for CD45+ lymphocytes twice weekly starting on day 5 and NK, T and B cell
amounts were determined based on staining for CD3, CD56, CD19.
NK Cell Biodistribution Analysis
0.2 x 106 cells NK cells as part PBMCs, were pre-activated ex vivo with PM21-particles
and 100 U/mL IL-2 for 2 days and were injected IP to NSG mice. Mice in all groups received
1,000 U of IL-2, IP, thrice weekly. Mice were also injected with 0 or 800 µg of PM21-particles,
IP, twice weekly. Mice were sacrificed 16 days after initial injection IP of PM21-PBMCs. On
day of euthanasia, bone marrow (femur), spleen, lung, brain and liver were collected, organs
were perfused while femur was washed to recover cells. Cells were stained with antibodies
against CD3, CD45, CD56, CD19 for flow cytometry analysis.
NK Cell Expansion from Different Donor Sources
PBMCs from different sources were pre-activated ex vivo for 2 days with PM21-particles
and 100 U/mL IL-2 for 2 days (PM21-PBMCs) and were injected IP to NSG mice. Mice in all
groups received 1,000 U of IL-2, IP, thrice weekly. Peripheral blood was analyzed by flow
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cytometry for CD45+ lymphocytes twice weekly starting on day 5 and NK, T and B cell amounts
were determine d based on staining for CD3, CD56, CD19.
Phenotype Analysis
PM21-PBMCs, activated ex vivo with PM21-particles for two days, were split and either
injected IP into NSG mice or further cultured ex vivo for 14 days. Mice were given 800 μg per
injection, IP twice weekly or ex vivo culture included 200 μg/mL of PM21-particles. NK cells
were obtained from ex vivo culture, from peripheral blood, or from wash of the abdominal cavity.
Cells were stained with respective fluorescent conjugated antibodies and were analyzed by flow
cytometry. Expression levels of the various cell surface proteins on NK cells were assessed with
fluorescence intensities of events gated by CD45+, CD56-, CD3- were inspected. Gates for the
positive populations were set based on FMO (fluorescence minus one)-isotype control samples.
Confocal Imaging
NK cells were expanded from PBMCs using PM21 particles for 12 days when NK cells
were at >80%. Cells were centrifuges and resuspended in 700uL SCGM + 10% FBS + 2mM
Glutamax + 1000U/mL IL2.
For the isolated NK cell setup, PBMC vials were thawed, cells were transferred to 40mL
RPMI + 10% FBS, centrifuged and resuspended in 1mL DPBS + 0.5%BSA + 2mM EDTA
(Isolation buffer; room temp). NK cell isolation was done using EasySep human NK cell
enrichment kit (Stem Cell Technologies Inc., Vancouver, BC, Canada). Cell count after isolation
showed 95.9% NK cells. 1mL SCGM + 10%FBS + 2mM Glutamax + 1000U/mL IL2 was added
to the cell suspension and transferred to a 6-well plate, placed in 37C, 5% CO2 incubator
overnight. SKOV-3/GFP-Luc cells plated in a 24-well glass bottom plate at ~60% confluency
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and allowed to adhere to the surface for 3-4 hours. Media was replaced by the NK cell
suspensions from both conditions mentioned above. Ultraview live cell imaging system was
used for imaging. GFP and DIC (differential interference contrast) channels were captures over
18 hours at 10X magnification
Leukemia cell lines Cytotoxicity Assay
NK cells were cultured for 14 days with PM21-particles. Target cells were labeled with
TFL4 dye (OncoImmunin, Gaithersburg, MD) prior to the assay. Expanded PM21-NK cells were
co-incubated with target cells at varying ratios for 4 hours, placed on ice and stained for 20
minutes with Annexin V-Alexa488 (BD Biosciences) and then analyzed by flow cytometry. The
amount of spontaneous target cell death was determined using a “Target Alone” control. Percent
cytotoxicity was determined by subtracting spontaneous cell death from target cell death and
then dividing by total target cells.
Autologous Patient NK Cell Cytotoxicity Assas
Cytotoxicity assays of patient derived NK cells against autologous AML tumor cells was
assayed with Annexin V (BD Bioscience). NK cells expanded for 18-20 days were stained with
TFL4 dye. Target tumor cells were co-cultured at 0.5 x 106 CD34+ cells/mL with NK cells at E:T
ratios of 1:1, 2:1, 5:1, and 10:1 for 2 hours in 37 °C, 5% CO2 atmosphere. The cells were then
centrifuged and resuspended in Annexin V labelling buffer containing Annexin V-FITC, antiCD34-PE, and anti-CD56-PC7 and incubated for 15 minutes at 4 °C. The labeled cells were
diluted to 250 µL and analyzed by flow cytometry on an Accuri instrument (BD Bioscience).
.
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Results
PM21 particles show better expansion of NK cells as compared to PM15 particles
It was recently reported that NK cells can be expanded using particles derived from
plasma membranes of K562-mb15-41BBL feeder cells (denoted PM15) [48]. The PM15particles perform very similar to K562-mb15-41BBL feeder cells to induce similar levels of NK
cell expansion, and the expanding NK cells also have the same characteristics of senescing after
~3 weeks of expansion. Since K562 cells engineered to express mb21, have been reported to
have better efficiency for NK cell expansion without senescence [49], PM-particles were
prepared from K562-mb21-41BBL cells, denoted PM21-particles, and tested for their NK cell
expansion capabilities.
PBMCs were cultured side-by-side with either PM15- or PM21-particles (200 μg/mL) for
28 days. NK cells stimulated with PM21-particles expanded more rapidly as compared to the
ones stimulated with PM15-particles, and the content of NK cells reached >90% by day 14 in
PM21-particle stimulated NK cell cultures compared to 21 days in PM15-particle stimulated
cultures (Figure 14 A,B). Cumulative analysis of NK cell expansions, at day 14±1 of culture,
showed that PM21-particles (mean 825 fold expansion, range 163-2,216, n=13) are significantly
(p=0.021) more effective as compared to PM15-particles (mean 424 fold, range 290-570, n=30)
(Figure 14 C). Furthermore, NK cells stimulated with PM21-particles expanded exponentially
during the period of 28 days reaching over 100,000 fold expansion, in contrast to the NK cell
expansion with PM15-particles which stalled by day 22 of culture due to senescence. Thus,
PM21-particles have improved NK cell expansion proficiency over the PM15-particles and
comparable to the K562-mb21-41BBL feeder cells from which they were derived [49].
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PM21 particle show expansion of NK cells from patient blood
The NK cell expansion capabilities of PM21-particles were further tested with PBMCs
from leukemia patients in remission. PM21-particles induced NK cell expansion relatively
efficiently from all three patient derived samples in 14 days of culture (113±7 fold for F021,
810±81 fold for M038, and 352±86 fold for M050, Figure 14 D). The expansion was specific for
NK cells where the percentage of NK cells of total CD45+ cells rose preferentially (Figure 14 E).
PM21 particle-pre-activated PBMCs show NK cell expansion in vivo which can be improved by
additional in vivo dosing of PM21
An unprecedented capability of the PM-particles would be as an injectable to spur in vivo
expansion. To test if PM21-particles stimulate in vivo NK cell expansion and to determine if ex
vivo pre-activation is required, NSG mice were injected IP with 0.1 x 106 NK cells as part of
either non pre-activated PBMCs or PM21-particle pre-activated PBMCs (PM21-PBMCs). Mice
injected with non pre-activated PBMCs had low amounts of NK cells in PB and only T cells
increased as a percentage of total CD45+ cells over 15 days post injection. In significant contrast,
PB of mice injected with PM21-PBMCs were found to have elevated amounts of NK cells that
peaked 12 days post IP injection (Figure 15). The NK cell content enriched to 53±8 % of CD45+
cells. In the same experiment, the efficacy was tested for in vivo IP application of PM21-particles
to promote better in vivo NK cell expansion. For mice injected with non pre-activated PBMCs,
additional in vivo PM21-particles did not stimulate NK cell expansion. However, applying
PM21-particles in vivo to mice grafted with PM21-PBMCs had an effect where NK cell amounts
were higher compared to the mice with PM21-PBMCs that did not receive in vivo PM21particles (Figure 15).
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To provide evidence that the PM21-particles induce in vivo NK cell proliferation,
analysis was performed with CTViolet labeled NK cells expanding in vivo at 6 days post IP
inoculation. The cells from mice injected with non pre-activated PBMCs showed none or very
little decrease in the CTViolet fluorescence, indicating that there was none or very few cell
divisions of NK cells (Figure 16, top panel). The NK cells from mice injected with PM21PBMCs showed significant diminishment of the CTViolet fluorescence intensities (Figure 16,
bottom panel). Fitting of the fluorescence intensities showed that the intensity decrease correlates
with the major population, dividing 7 cell divisions in vivo within 6 days. For the NK cells
obtained from mice that received IP injections of PM21-particles, one more division can be
observed. This additional doubling with administration of the in vivo PM21-particles correlates
with the higher NK cell amounts observed in PB with in vivo PM21-particles.
Enhanced NK cell expansion due to in vivo delivery of PM21 is dose-dependent
To further verify if in vivo delivered PM21-particles enhance in vivo NK cell expansion,
a dose dependence of in vivo PM21-particles was studied (Figure 17). A dose dependent increase
in NK cells in PB was observed from 0 to 800 μg of PM21-particles per injection. At a dose of
800 μg, 470±40 NK cells per μL of PB was observed at 12 days after IP injection of the PM21PBMCs. This NK cell concentration in PB was 5 fold higher than the concentration that is
generally thought to be therapeutically efficacious [98]. The dose dependent effect for in vivo
expansion was specific for NK cells where T cell amounts did not increase significantly (Figure
17 b, c). At a higher amount of 1,600 µg per injection, PB NK cell amounts diminished, similar
to the effect observed ex vivo where ~200-400 µg/mL is optimal for PM21-particles (data not
shown) or PM15-particles and higher amounts attenuated NK cell expansion [48].
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In vivo expanded NK cells home to different organs and homing increases with in vivo dosing of
PM21
The observation of significant amounts of NK cells in PB shows that NK cells expand in
the peritoneal cavity along with IP injection of PM21-PBMCs, can migrate out from the cavity to
the PB. To verify that the adoptively transferred NK cells can migrate to potential sites of
disease, NK cells in various organs were quantified (Figure 18). Human NK cells were found in
every organ inspected, and higher amounts of NK cells were found in organs from mice treated
in vivo with 800 µg of PM21-particles, all significantly higher (p<0.05) except in livers.
Furthermore, the organs from the mice treated with 800 µg of PM21-particles had higher
percentage of NK cells as a fraction of total CD45+ cells.
NK cell expansion with PM21 is independent of the PBMC source
The mice based studies described here showed that the procedure combining ex vivo short
pre-activation with PM21-particles and in vivo administration of PM21-particles induces
significant in vivo NK cell expansion, potentially in the therapeutically relevant range. To show
consistency, necessary for clinical use, the procedure was applied to leukocyte sources from
three different donors (different from those used in other experiments) (Figure 19). The average
amount of NK cells in both PB and abdominal wash was relatively consistent between leukocyte
sources (p=0.8). The percentage of NK, T cells and other CD45+ cells was also very consistent
for mice within the group injected with the PM21-PBMCs from a particular leukocyte source
(n=3) and also between leukocyte sources L8 and L10.
Phenotype of NK cells expanded with PM21-particles
The anti-tumor cytolytic activity of NK cells is determined by the balance of stimuli from
activating and inhibitory signals. Here, a detailed comparative inspection was performed for the
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PM21-particle stimulated NK cells 1) expanded ex vivo with PM21 for 12 days, 2) expanded in
vivo and isolated from PB, and 3) expanded in vivo and isolated from the abdominal wash (AW).
These comparisons were made using cells from a single donor in all of the settings and
performed in parallel (Figure 20).
Presence of CD16, the Fcγ receptor, on NK cells is required for effective antibody
dependent cytotoxicity (ADCC). Nearly all NK cells from in vivo expansion show expression of
CD16 (97% and 87% for PB and AW, respectively). CD94 is a surface receptor that forms
heterodimeric complexes with NKG2C or NKG2A. About half of the NK cells expanded ex vivo
have CD94 expression. For NK cells expanded in vivo, cells from the AW (64±9%) have higher
expression than NK cells from PB (38±13%). Receptors of the NKG2 family both bind to CD94,
inclusive of NKG2C as an activating receptor and NKG2A as an inhibitory receptor. The ex vivo
expanded NK cells had relatively low expression of NKG2C, but NK cells from the AW were
higher (53±8%) and even more increased in PB (61±2%). The fraction of NK cells that express
NKG2A were higher in the AW (82±8%) than PB (67±12%) and those from ex vivo (74%).
NKG2D is another important activating receptor found on NK cells and its expression was found
on 61±6% of AW NK cells, 26±3% from PB and about 75% of NK cells expanded ex vivo. The
expression of CD62L, known to be correlated with bone marrow homing, was higher for NK
cells in PB (63±10%) and lower for that in the AW (39±14), which is consistent with the
expression being higher on cells that were mobilized. NKp44 and NKp46 are members of the
natural cytotoxicity receptor family and play a role in NK cell mediated cytolysis. NKp46 was
expressed on NK cells from both PB (76±9%) and AW (89±5%). NKp44 was relatively poorly
expressed in these NK cells from all the sources. On the other hand, NKp46 was well expressed
from both PB (89±5) and AW (76±9). TRAIL is a ligand on NK cells that induces apoptosis of
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targets via the death receptor pathway. TRAIL was expressed on 36±6% of NK cells from AW,
20±4% of PB and 26% of ex vivo-expanded cells. KIR2D is the killer immunoglobulin-like
receptor (KIR) 2D subtype and a minority (about 1/3) of the NK cells in vivo or ex vivo
expressed KIR2D. The proportion of CD8+ and CD4+ T cells were analyzed and it was found
that CD8+ T cells were more abundant than CD4 T cells from the in vivo samples. We also tested
for presence of NK suppressive Treg cells and very few (<0.1% of all CD3+ cells) were observed
in in vivo samples.
PM21-stimulated NK cells are cytotoxic against tumor cells in vitro
In order to test the cytotoxic capacity of PM21-expanded NK cells in comparison to
fresh, non pre-activated NK cells, SKOV-3/GFP-Luc cells were co-incubated with them and
imaged over time. Figure 21 shows PM21-expanded NK cells attacking attached SKOV-3/GFPLuc cells causing them to lift, aggregate and die (top panel). Whereas, isolated NK cells,
stimulated with 10,000 U IL-2 overnight show close minimal activity against attached tumor
cells.
Apart from ovarian tumor cells, PM21-activated NK cells also showed cytotoxicity
against different leukemia cell lines such as K562 (Chronic myelogenous leukemia or CML),
HL-60 (Acute promyelocytic leukemia or APML) and KG-1 (Acute myelogenous leukemia or
AML). Also, PM21-expanded NK cells from PBMCs of one of the leukemia patients (F021) in
remission (shown in figure 14 D,E) were tested for cytotoxicity in an autologous setting against
tumor blasts obtained from the same patient during active disease. At a relatively low effector to
target ratio (E:T) of 1:1, 78±3% of tumor cells were apoptotic. Thus, this method of NK cell
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stimulation could potentially be used for the treatment of various types of cancers and could
possibly prove to be successful in an autologous transplant setting.
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Figures
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Figure 14: PM-21 particles expand cytotoxic NK cells efficiently and selectively.
Peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte source and seeded at 0.1 x 106 NK cells/mL in SCGM
supplemented with 10% FBS, 2 mM Glutamax and 50 U/mL IL-2. PBMCs were stimulated with PM15 (□, black) or PM21 (○, blue) particles
at 200 μg/mL for 27 days, the cell content was tested every 2-3 days and shown are relative fold of NK cell expansion A) and the percentage
of suspension cells B). PM21-particles (825 ± 188 fold, N=13, 4 donors) (blue) are more efficient for NK cell expansion compared to PM15particles (425 ± 71, N=35, 9 donors) (black) based on cumulative analysis of day 14 data for NK cell expansion C). PBMCs isolated from
three AML patients in remission were cultured for 14 days with PM21-particles (200 μg/mL), seeded at 0.5 x 106 NK cells/mL in SCGM with
10% FBS, 2 mM Glutamax, 50 U/mL IL-2. Shown is fold of NK cell expansion from the primary PBMCs D) and lymphocyte content E)
(CD56+CD3- NK cells (●, red), CD56-CD3+ T cells (■, blue) and CD56+CD3+ NKT cells (▲, black)). PBMCs from patient F021 were
cultured for 14 days as previously above and autologous cytotoxicity toward AML tumors from the same patient was analyzed (Experiment
courtesy of Jeremiah L. Oyer, Copik Lab).
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Figure 15: Pre-activation of unselected PBMCs with PM21-particles induces in vivo NK cell expansion.
NSG mice were injected IP with 2x106 cells of either pre-activated PBMCs ex vivo with PM21-particles (left) or non pre-activated PBMCs
and 100 U/mL IL-2 for two days (PM21-PBMCs). Mice in all groups received 1,000 U of IL-2, IP thrice weekly. Groups of mice were also
injected with 400 µg of PM21-particles, IP twice weekly. Peripheral blood was drawn by sequential cheek bleeds and analyzed by flow
cytometry for CD45+ human lymphocytes twice weekly starting on day 6. Cell amounts were determined based on staining for CD3, CD56,
CD19. The top plots in each experimental group show concentration of hNK cells per µL of PB. The bottom plots show the percentage of NK
cells (○, red) and T cells (, black) as fraction of total CD45+ cells.
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Figure 16: Proliferation analysis evidences in vivo NK cell expansion from PM21-PBMCs.
A, B) Non pre-activated PBMCs C, D) PM21-PBMCs. B, D) 2 groups were injected with 400 µg of
PM21-particles. Histograms of the CT Violet fluorescence was analyzed through curve fitting using the
Proliferation analysis suite within FlowLogic.
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Figure 17: In vivo application of PM21 allows increase of NK cells in peripheral blood.
a) The top plots in each experimental group shows concentration of hNK cells per µL of PB. The bottom
plots shows the percentage of NK cells (○, red) and T cells (, black) as fraction of total CD45+ cells. b)
Analysis of PB samples from day 12 after initial injection IP of PM21-PBMCs shows a dose dependent
increase of hNK cells with respect to in vivo PM21-particle dose; c) while no significant dose dependent
increase in total CD3+ T cells was observed.
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Figure 18: In vivo expanded NK cells bio-distribute to key physiological sites and the NK cell bio distribution is increased with in vivo
application of PM21-particles.
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Figure 19: In vivo NK cells expansions from different donor sources are consistent.
A) Concentration of NK cells in blood 12 days after IP PBMC injection and C) the amount of NK cells
collected in a wash of the abdominal cavity 14 days after IP PBMC injection were similar between the
different groups injected with different NK cell sources (p=0.84 for PB and p=0.69). B, D) The
corresponding cell content of NK cells (○, red), T cells (□, blue) and other CD45+ cells (, black) were
also consistent between the groups injected with different PBMC sources in the peripheral blood and in
the abdomen. The thick bar represents the mean.
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Figure 20: Comparative phenotype analysis of PM21-NK cells expanded from in vivo and ex vivo sources.
NK cells were obtained from ex vivo culture (left), from peripheral blood (PB, middle), or from wash of
the abdominal cavity (AW, right). Plots show the expression of important activating and inhibitory
receptors and markers of NK cells involved in different cytotoxicity pathways such as ADCC and death
receptor pathways.
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Figure 21: PM21 particle expanded NK cells kill SKOV-3/GFP-Luc cells in vitro.
Top panel of images shows PM21-expanded NK cells attacking adhered SKOV-3/GFP-Luc cells over time and the bottom panel shows
isolated NK cells, not pre-activated with PM21 showing minimal activity against adhered SKOV-3/GFP-Luc cells, leaving the tumor cells
attached to the plate.
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Figure 22: PM21-particle expanded NK cells kill leukemia cell lines and patient tumor in an autologous setting.
A) Percentage cytotoxicity of PM21 expanded NK cells against K562 (CML), HL-60 (APML) and KG-1 (AML) cell lines. Plots depict one
representative cytotox assay and each data point was determined in duplicate with the error bars depicting the standard deviation. B) PM21NK cells (from F021 patient PBMC) labeled with TFL4, co-incubated (2 hours) at indicated E:T ratios with AML cells from the same patient
during active disease, and analyzed by flow cytometry. The amount of spontaneous dead target cells was determined using a “Target Alone”
control. Each data point was determined in duplicate (Experiment courtesy of Jeremiah L. Oyer, Copik Lab).
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Discussion
PM21-particles facilitate ex vivo and in vivo NK cell expansion to therapeutically
relevant amounts.
Adoptive NK cell therapy holds high promise as a cancer therapy for initial treatment and
remission maintenance of various tumors. A requirement for therapeutic use of NK cells is a
method for rapid and selective NK cell expansion that is safe, simple, and overall therapeutically
effective. Several cytokine and feeder cell based methods are currently being clinically
investigated and the methodology using K562-mb21-41BBL cell line is among the most
effective for ex vivo NK cell expansion. While feeder cell methods are effective for providing a
high initial dose and can allow for multiple dosing, the ability of the ex vivo expanded NK cells
for homing to the bone marrow may be affected in leukemia treatment and in vivo persistence of
the infused NK cells may not be optimal. The combined ex and in vivo PM21-particle based NK
cell expansion method described here could significantly enhance the efficacy of NK cell
adoptive therapy.
Importantly, PM21-particles can be used for in vivo stimulation to promote in vivo
expansion and persistence. The methodology developed here used a short 2 day ex vivo preactivation, followed by in vivo administration of PM21-particles. In vivo application of the
PM21-particles induces higher in vivo NK cell expansion, which is dose dependent on the in vivo
applied PM21-particles. With our current optimized procedure, PB NK cells were increased by
an average of 360-fold between days 5 and 12 after IP injection of PM21-PBMCs, with perhaps
even greater fold of expansion in the intraperitoneal cavity. For comparison, it was shown in a
recent study [109] that following IV infusion of 1-2 x 106 NK cells only about 5 to 17 NK cells
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per µL of blood were observable on day 14 after infusion. In contrast, PM21 particles resulted in
>400 NK cells/µL of blood on day 12 after IP infusion of 2.0 x 106 PM21-PBMCs (11%, i.e. 0.2
x 106 NK cells). Moreover, the former study used 5 µg (~50,000 U) of either IL-2 or IL-15 thrice
weekly, whereas a relatively low dose of IL-2 (1,000 U/injection, thrice weekly) was used in our
study. In a different study [47], 30 x 106 NK cells were preferentially expanded ex vivo with
K562-mb15-41BBL feeder cells and then were injected IV followed by tracking the injected
human lymphocytes using anti-CD45 antibody (not by a combination of anti-CD56 and antiCD3). However, the deficiencies in this method were that high dose of IP injected IL-2 (25,000
U/daily) was required for lymphocyte persistence and NK cell concentrations were implied but
not determined. Therefore, in comparison to these previous studies, the resultant expansion of
NK cell numbers in vivo from the PM21 particle method is unprecedented and a unique
capability of the PM21 particles.
Here, the route of delivery of the PM21-PBMCs to NSG mice was by the IP injection,
similar to previous pre-clinical studies [47, 63]. In comparison, the PM21 particle based method
has several advantages. First, the combination of ex vivo pre-activation and in vivo stimulation
with PM21-particles enables the use significantly fewer unselected PBMCs compared to
cytokine activation of isolated NK cells [63], which are obtained from blood apheresis followed
by extensive laboratory processing for NK cell enrichment. Second, the PM21-particle based
method only requires a short 2 day pre-activation, instead of two week culture based expansion
[47], and therefore may allow for better preservation of physiologically relevant functionality.
Third, the current method allows for significantly greater in vivo expansion of NK cells and in
vivo persistence without the use of high dose IL-2, which has been associated with clinical
toxicity. For intraperitoneal tumors such as ovarian cancer, the advantages of the currently
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described method may significantly enhance the overall anti-tumor effect. In the absence of
intraperitoneal tumors, the intraperitoneal cavity still may provide an environment for PM21particle to facilitate in vivo expansion, as shown clearly shown by proliferation analysis with CT
Violet, so that the NK cells can migrate out at significant amounts to the PB and circulate to
other organs. NK cells were not only observed in PB, but were found in organs and also were
more abundant with in vivo application of PM21-particles. The NK cell amounts measured in
bone marrow is comparable to those in a study [110] using NK cells generated from CD34+
umbilical cord blood stem cells, indicating that these NK cells are competent for marrow
homing.
Phenotyping of NK cells expanded in parallel ex vivo or in vivo (Figure 20) indicated that
the resulting cells were similar, irrespective of the approach. Interesting differences were
observed with respect to expansion of NKG2A- and NKG2C+ subpopulations that were mostly
observed with NK cells expanded in vivo but not in ex vivo [111]. NKG2C+ NK cell populations
have been observed during viral reactivation, associated with “memory-like” response and were
recently shown to be dependent on monocytes for production of IL-12 [111-113]. Presence of
NKG2C+ NK cells in patients with CMV reactivation after stem cell transplantation for AML
was also associated with better outcomes and less relapse [114]. Also, significant population of
NKG2A- NK cells that should be resistant to HLA-E induced inhibition may be important in
treatment of multiple myeloma patients where cells downregulate HLA class I but express HLAE to evade NK cells response [115]. Approaches aimed at downregulation of NKG2A have been
proposed as a means to improve NK cell cytotoxicity and thus their therapeutic potential [116].
Since ex vivo expanded cells were mostly NKG2A+, shortening the time of ex vivo culture with
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subsequent in vivo expansion may provide additional benefit in generation of NK cells with
greater phenotypic diversity and potentially good cytotoxicity against targets.
Potential clinical utility of PM21-particles. The capabilities of PM21-particles for NK
cell expansion may allow wider use of adoptive NK cell therapy for cancer treatment and
potentially for other maladies as well. The PM21-particles can easily be substituted for the feeder
cells currently used in clinical trials to ease logistics and mitigate risks. For regulatory
jurisdictions where the use of tumor derived feeder cells are prohibited or approval is difficult to
obtain, the PM21-particles are a ready solution of ex vivo expansion and activation. Moreover, in
vivo administration of the PM21-particles can further expand the NK cells in vivo, an
unprecedented capability, and possibly diminish T cell expansion to mitigate GVHD. For
treatment of peritoneal cancer and other intraperitoneal tumors such as in persistent ovarian
epithelial cancer or desmoplastic small-round-cell tumor, this NK cell expansion method could
potentially be clinically translated. Anti-tumor efficacy experiments for elimination of
intraperitoneal ovarian tumor are currently underway.
Importantly, the NK cells expanded by this method biodistribute out from the abdominal
cavity to peripheral blood and multiple organs that are potential sites of various other cancers.
While the IP route of injection is unconventional for treatment of hematological malignancies,
delivery of NK cells by this IP path results in PB concentration of NK cells that would be
relevant for AML treatment. Therefore, future exploration and testing may be worthwhile to
consider for IP delivery of NK cells and PM21-particles for treatment of non IP cancers such as
AML.
The particle based approach for NK cell specific signaling could be a platform to include
other signaling molecules or even a vehicle for packaged delivery of agents for further targeted
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stimulation of NK cells to enhance homing, anti-tumor cytotoxicity and persistence. The PM21particles can be highly complementary with all the innovative NK cell specific immunotherapy
methods (check point inhibitors [117], CARs [118-121], bispecific killer cell engagers (BiKE)
[122], Diptheria toxin fused IL-2 for Treg depletion [109], etc.) being developed and with the
effects of these being beneficially compounded upon in vivo expansion of NK cells with PM21stimulation. Even as a pre-clinical utility, the currently described method can allow an
unprecedented method to study such combination methods. While of course there are murine
models, there are no other methods to study human NK cells that can be present in vivo for a
significant duration.
To summarize, this procedure with PM21-particles allows in vivo preferential NK cell
expansion at levels typically only achieved with ex vivo expansion with feeder cells, but without
the need of cell culture with feeder cells or high cytokine doses that are toxic. Furthermore,
PM21-PBMCs with in vivo delivery of PM21-particles could be used in autologous settings, to
take advantage of beneficial synergistic effect of other immune cells on NK cell function [123125] and further combined with other strategies such as anti-KIR antibodies or BiKEs to
maximize NK cell cytotoxicity [94, 122, 126]. Thus this method meets the criteria for generation
of NK cells for potential therapeutic efficacy while being simple, more amenable for clinical
translation, and can be impactful for treatment of cancer or other maladies.
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CHAPTER 4: CONCLUSION
Evidence over the past several years has shown that ovarian cancers are immunogenic in
nature. As discussed before, there are credible chemotherapeutic drugs and procedures used in
addition to cytoreductive surgery for the treatment of primary tumors. The challenge is to
develop new feasible strategies that offer maximum clinical benefit to treat relapsed tumors.
Studies suggest that platinum based chemotherapeutics can trigger the immune system by
causing cell death, leading to anti-tumor immune response [127, 128]. Since platinum based
drugs are the main agents used in front-line ovarian cancer treatment and are involved in
enhancement of immunogenic cell death of tumor cells, there’s a strong rationale for
development of immunotherapeutic strategies as adjuvant therapy against ovarian tumors.
Chapter 2 delineates the importance of innate NK cells as a main effector population in the
PBMCs that act as the first-line of defense against the tumor. The study implies that there is
cooperation or synergy within the PBMC population that NK cells require for their activity. This
could explain the lack of NK cell responsiveness seen in the clinic because they are usually
expanded and administered as an isolated population. The study underscores the importance of
further development of existing NK cell based therapeutic strategies, mainly adoptive cell
transfer, specially focusing on overcoming the side effects. Adoptive cell therapy using NK cells
has shown promising results against some cancers such as leukemia and melanoma, but there is
still a large scope for improvement in the understanding of NK cell function especially with
respect to solid tumors such as ovarian cancer.
Miller and co-workers have defined a guideline for clinically efficient NK cell expansion
as achieving 100 NK cells/μL of blood 14 days following infusion [98]. The NK cell expansion
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strategies including in vivo and ex vivo expansion using IL-15/IL-2 stimulation has marginal
benefits and several side-effects. There has been improvement in ex vivo expansion using feeder
cell co-cultures with modified K562 cell line expressing membrane bound cytokines, mainly IL15 and IL-21. Although these feeder cell-based methods offer improvement in NK cell
expansion, there are other challenges pertaining to long ex vivo culturing time periods.
Expansion with K562-mb15-41BBL may results in, first, senescence of NK cells and second,
loss of their CD16 receptor leading to decrease in the capacity to mediate one of the major
effector functions through ADCC. Expansion with the membrane bound IL-21 variant of the cell
line overcomes the problem of senescence but issues with exhaustion, in vivo persistence and the
ability to home to different organs remain. Besides this, the logistics of using feeder cells for
expansion limit feasibility of their use in clinic.
Taking into consideration, all these drawbacks and challenges, Copik et al devised the
method to expand NK cells using plasma membranes obtained from K562-mb15-41BBL cells
and showed that NK cell expansion was comparable to that from the feeder cells the membranes
were derived from and that the cells expanded ex vivo using this method were cytotoxic [48].
This study showed that the use of plasma membrane bound cytokines including but not limited to
IL-15 could perhaps be a strong alternative to the existing feeder cell co-culture methods,
without associated drawbacks that have been discussed above.
In the light of advantages seen from K562-mb21-41BBL expanded NK cells over that of
K562-mb15-41BBL, such as better expansion and lack of senescence, same strategy was applied
to obtain membrane bound IL-21 and 41BBL, which is the focus of the study presented in
chapter 3. IL-21 is a cytokine secreted mainly by CD4+T cells and belongs to the γ-chaindependent family of cytokines such as IL-2 and IL-15 [129]. Besides benefitting NK cells in
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terms of activating and promoting their survival, IL-21 is also shown to increase the expression
of co-stimulatory molecules and NK cell effector molecules such as perforins and granzyme
[130]. These findings in addition to advantages of K562-mb21-41BBL expanded NK cells as
discussed before, strengthen the rationale for using this interleukin for stimulating NK cell
expansion and cytotoxicity. Experiments discussed in chapter 3 clearly show that PM21 particles
show better in vitro expansion of NK cells as compared to that from PM15 particles. It also
shows that NK cells pre-activated with PM21 can expand in vivo and that this expansion can be
augmented by further administration of PM21 in vivo. NK cells expand in the peritoneal cavity,
migrate to the peripheral blood and home to different organs. Besides this, these particles were
able to expand NK cells from patients in remission and they were shown to be cytotoxic against
the same individual’s tumor cells, which gives an indication that this strategy might be helpful in
autologous NK cell therapy as well. Most importantly, PM21 pre-activated NK cells showed
cytotoxicity against SKOV-3/GFP-luc cells in vitro along with some leukemia cell lines. During
in vivo expansion, not only did NK cells expand to 360 fold in 5 to 12 days (>400 NK cells/μL of
blood on day 12, which is way more that the set benchmark), but they constituted high
percentage of total CD45+ cells in mouse blood, indicating that the expansion was NK cell
specific with low T cell numbers.
Current studies in our group include, determining in vivo cytotoxicity of PM21 stimulated
NK cells in tumor models such as the ovarian cancer model discussed in chapter 2. To further the
clinical relevance, efficacy could also be tested using patient derived xenograft mouse models of
ovarian cancer, in terms of overall survival. Future studies will involve the study of in vivo
cytotoxicity against leukemia cell lines. Considering hindrances because of lack of appropriate
models for the disease, perhaps an orthotopic model will be developed for leukemia and then the
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efficacy of PM21 stimulated NK cells would be studied in terms of homing to the bone marrow
in the presence of tumor and cytotoxicity against that tumor. If and when tumor clearance in vivo
is established, another interesting avenue would be to study NK cell memory possibly by rechallenging the mice with tumors. Another relatively unknown aspect of this study is the
trafficking of the plasma membrane particles in vivo and how it may affect NK cell expansion.
There are indications of PM21 particles being taken up by some other immune cell types in the
injected PBMC population (data not shown). Such clarifications will shed light on the
involvement and importance of other immune cell types in augmenting or diminishing NK cell
expansion, persistence and cytotoxic efficacy. By dissecting the involvement of different
signaling components essential for NK cell activation, plasma membranes could possibly be used
to express involved molecules, for targeted stimulation of NK cells to enhance various aspects
important for NK cell based immunotherapy. For example, currently experiments are underway
to develop membrane bound IL-2 in order to make NK cells independent of exogenous or T cellprovided IL-2 for proliferation.
Overall, the first part of this study shows the relevance of an innate immune cell type in
tumor cell recognition and mounting a first-line defense that resulted in complete clearance of
residual ovarian tumors, which is relatively under-appreciated and unexploited in the field of
immunotherapy for cancer. The second part of the study shows a novel methodology of NK cell
expansion that has tremendous potential in advancing the field of NK cell based immunotherapy
for ovarian and other cancer types. This strategy could perhaps also be combined with other
immunotherapies that are currently being tested in the clinic and that have great potential for
ovarian and other types of cancers, such as checkpoint blockade, mAb therapies, vaccines etc.
Tumor cells can adopt various escape mechanisms simultaneously in order to evade immune
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recognition. Thus, it is rational to combine immunotherapies in order to target tumor-escape
mechanisms at various levels, possibly resulting in cooperation or synergy amongst different
strategies and achieving maximum benefit, hopefully curing cancer.
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